Optimize Formulation of VSA Adjuvant
$600,000N43FY2022AINIH
Adjuvax Llc, Hoover AL
Investigators
Abstract
The contract supports the development of a saponin as a vaccine adjuvant. The adjuvant development activities are being conducted within the context of vaccines to protect against SARS-CoV-2 and pneumococcal infection.
View original record on NIH RePORTER →